Trimeris, Inc. and F. Hoffmann-La Roche Ltd. Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors

MORRISVILLE, N.C.--(BUSINESS WIRE)--Trimeris, Inc. (NASDAQ: TRMS) today announced that it has reached agreement with F. Hoffmann-La Roche Ltd (“Roche”) for the return of all rights to joint patents and other intellectual property related to next-generation HIV fusion inhibitor peptides to Trimeris that fall under the Roche-Trimeris 2000 Research Agreement. In return, Trimeris has agreed to pay Roche a nominal royalty on future net sales of TRI-1144 up to a specified limit.